Fresh Start For Insmed, Added Biosimilar Capabilities For Merck In $130M Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
By purchasing Insmed’s follow-on biologics pipeline and facility, Merck BioVentures is poised for bigger attack on Amgen blockbusters.
You may also be interested in...
Insmed Gets New Direction By Absorbing Transave And Lead Program Arikace
Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.
Insmed Gets New Direction By Absorbing Transave And Lead Program Arikace
Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry